| Literature DB >> 26967389 |
Quan Zhou1, Fengli Chen2, Zhongting Fei3, Jiali Zhao1, Yong Liang4, Wei Pan1, Xingxiang Liu3, Donghui Zheng4.
Abstract
Osteosarcoma (OS) is the most common primary malignant bone tumor in adolescents and young adults. However, the essential mechanisms underlying osteosarcomagenesis remain obscure. The HOTAIR, a well-known long noncoding RNA (lncRNA), is involved in pathogenesis and progress of multiple tumors. To reveal the potential role of lncRNA HOTAIR in OS carcinogenesis, we conducted a two-stage, case-control study among Chinese population with 900 OS cases and 900 controls to evaluated associations of its genetic variants with OS risk. We found that C allele of rs7958904 was associated with a significantly decreased OS risk when compared with G allele (OR: 0.77; 95% CI: 0.67-0.90; P = 6.77×10-4). Functional analyses on HOTAIR Expression showed that the expression level of HOTAIR in OS tissues was significantly higher than that in corresponding normal tissues, and subjects with the rs7958904 CC genotype had significantly lower HOTAIR RNA levels than those of other genotypes. This should be the first study to examine the association between HOTAIR variants and OS risk.Entities:
Keywords: HOTAIR; lncRNA; osteosarcoma; susceptibility; variant
Mesh:
Substances:
Year: 2016 PMID: 26967389 PMCID: PMC4991428 DOI: 10.18632/oncotarget.7957
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Genetic variants of HOTAIR and Osteosarcoma risk
| Stage | Genotype | Cases | Controls | Adjusted OR (95% CI) |
|---|---|---|---|---|
| AA | 423 | 425 | 1.00 (reference) | |
| AG | 62 | 64 | 0.97 (0.67-1.42) | |
| GG | 15 | 11 | 1.37 (0.62-3.01) | |
| G vs A | 1.08 (0.79-1.47) | |||
| P trend | 0.638 | |||
| GG | 310 | 338 | 1.00 (reference) | |
| AG | 150 | 135 | 1.21 (0.92-1.60) | |
| AA | 40 | 27 | 1.62 (0.97-2.68) | |
| A vs G | 1.28 (1.03-1.59) | |||
| P trend | ||||
| GG | 267 | 270 | 1.00 (reference) | |
| AG | 106 | 108 | 0.99 (0.72-1.36) | |
| AA | 27 | 22 | 1.24 (0.69-2.23) | |
| A vs G | 1.07 (0.83-1.36) | |||
| P trend | 0.614 | |||
| GG | 295 | 266 | 1.00 (reference) | |
| CG | 180 | 194 | 0.83 (0.64-1.09) | |
| CC | 25 | 40 | 0.56 (0.33-0.95) | |
| C vs G | 0.79 (0.65-0.97) | |||
| P trend | ||||
| GG | 229 | 200 | 1.00 (reference) | |
| CG | 140 | 152 | 0.80 (0.60-1.08) | |
| CC | 31 | 48 | 0.56 (0.35-0.92) | |
| C vs G | 0.75 (0.60-0.93) | |||
| P trend | ||||
| GG | 524 | 466 | 1.00 (reference) | |
| CG | 320 | 346 | 0.82 (0.67-1.00) | |
| CC | 56 | 88 | 0.57 (0.40-0.81) | |
| C vs G | 0.77 (0.67-0.90) | |||
| P trend |
Adjusting for age, and gender
HOTAIR rs7958904 and Osteosarcoma risk stratified by co-variables
| Gender | ||||
| Male | GG | 1.00 (reference) | ||
| CG | 0.81 (0.63-1.03) | |||
| CC | 0.55 (0.39-0.78) | |||
| C vs G | 0.79 (0.66-0.94) | |||
| Female | GG | 1.00 (reference) | ||
| CG | 0.84 (0.69-1.02) | |||
| CC | 0.58 (0.39-0.87) | |||
| C vs G | 0.74 (0.57-0.95) | |||
| Tumor location | Extremities | GG | 1.00 (reference) | |
| CG | 0.81 (0.66-1.00) | |||
| CC | 0.56 (0.38-0.82) | |||
| C vs G | 0.77 (0.66-0.90) | |||
| Other | GG | 1.00 (reference) | ||
| CG | 0.85 (0.70-1.03) | |||
| CC | 0.59 (0.37-0.95) | |||
| C vs G | 0.79 (0.63-0.99) | |||
| Age | ≥23.5 | GG | 1.00 (reference) | |
| CG | 0.84 (0.70-1.01) | |||
| CC | 0.59 (0.42-0.82) | |||
| C vs G | 0.79 (0.66-0.95) | |||
| <23.5 | GG | 1.00 (reference) | ||
| CG | 0.79 (0.61-1.03) | |||
| CC | 0.56 (0.36-0.87) | |||
| C vs G | 0.75 (0.59-0.95) |
Figure 1HOTAIR RNA expression (mean ± SD) in normal and OS tissues grouped by SNP rs7958904 of HOTAIR
presents the distribution of selected characteristics among OS cases and controls
| Stage 1 | Stage 2 | |||||
|---|---|---|---|---|---|---|
| Category | Cases ( | Controls ( | Cases ( | Controls ( | ||
| Age (yr) | ||||||
| Mean ± SD | 23.5±8.5 | 23.3±7.1 | 0.686 | 23.7±5.5 | 23.2±5.2 | 0.187 |
| Gender | ||||||
| Male | 300 (60.0%) | 295 (58.9%) | 0.747 | 237 (59.2%) | 238 (59.5%) | 0.943 |
| Female | 200 (40.0%) | 205 (41.1%) | 163 (40.8%) | 162 (40.5%) | ||
| Tumor location | ||||||
| Extremities | 394 (78.7%) | 320 (80.0%) | ||||
| Other | 106 (21.3%) | 80 (20.0%) | ||||
| Metastasis | ||||||
| Yes | 238 (47.5%) | 207 (51.8%) | ||||
| No | 262 (52.5%) | 193 (48.2%) | ||||
| Enneking stage | ||||||
| I-II | 301 (60.2%) | 240 (59.9%) | ||||
| III | 199 (39.8%) | 160 (40.1%) | ||||